Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE AND ETHINYL ESTRADIOL 10 11 versus PROVERA.
Head-to-head clinical analysis: NORETHINDRONE AND ETHINYL ESTRADIOL 10 11 versus PROVERA.
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11) vs PROVERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive; ethinyl estradiol suppresses follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, inhibiting ovulation; norethindrone alters cervical mucus, endometrial lining, and sperm penetration.
Provera (medroxyprogesterone acetate) is a progestin that binds to progesterone receptors, suppressing gonadotropin secretion, inhibiting endometrial growth, and inducing secretory changes in the endometrium. It also has antigonadotropic effects by reducing LH and FSH release from the pituitary.
One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg for days 1-10; norethindrone 1 mg/ethinyl estradiol 35 mcg for days 11-21) orally once daily for 21 days, followed by 7 days of placebo or no tablets.
Oral: 5-10 mg daily for 5-10 days for secondary amenorrhea; 5-10 mg daily for 12-14 days per cycle in combination with estrogen for endometrial hyperplasia; 400-1000 mg/day IM monthly for endometriosis.
None Documented
None Documented
Norethindrone: terminal half-life ~7-8 hours. Ethinyl estradiol: terminal half-life ~13-27 hours (mean ~17 hours). Clinical context: Steady-state achieved within ~5-10 days; dosing interval based on maintaining contraceptive efficacy.
Terminal elimination half-life is approximately 12-17 hours for medroxyprogesterone acetate (oral). With depot intramuscular injection, the half-life is extended to approximately 50 days due to slow absorption from the injection site.
Norethindrone and ethinyl estradiol are primarily eliminated via renal excretion. Norethindrone is excreted as glucuronide and sulfate conjugates, with ~50% renal and ~20-30% fecal. Ethinyl estradiol is extensively metabolized; ~40% renal and ~60% fecal as conjugates.
Renal (50-60% as metabolites), biliary/fecal (30-40%). Less than 1% excreted unchanged.
Category D/X
Category C
Progestin
Progestin